Abstract
Oncological drugs often face challenges such low solubility and poor bioavailability, leading to higher required doses, increased systemic toxicity, and adverse effects. Axitinib, a potent tyrosine kinase inhibitor targeting VEGF receptors, shows promising potential for glioblastoma treatment due to its anti-angiogenic properties. However, its therapeutic performance in brain tumors is hi…